• Annovis Bio entered a collaboration with Weave Bio to support preparation of a planned U.S. NDA for Alzheimer’s drug candidate buntanetap.
• Weave’s AI platform will be used to draft, review, and manage NDA documents ahead of the Phase 3 trial’s 6-month top-line readout.
• Annovis retains responsibility for content, verification, and final approval of all documents submitted to the FDA.
• The pivotal Phase 3 Alzheimer’s study enrolled 862 biomarker-confirmed patients versus a 760 target.
• Database lock is targeted for December 2026; top-line symptomatic data are expected in March 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230800PRIMZONEFULLFEED9831877) on September 23, 2026, and is solely responsible for the information contained therein.